Format

Send to

Choose Destination
J Clin Invest. 2007 Mar;117(3):557-67.

Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Author information

1
Devision of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. j-varga@northwestern.edu

Abstract

A unique feature of systemic sclerosis (SSc) that distinguishes it from other fibrotic disorders is that autoimmunity and vasculopathy characteristically precede fibrosis. Moreover, fibrosis in SSc is not restricted to a single organ, but rather affects many organs and accounts for much of the morbidity and mortality associated with this disease. Although immunomodulatory drugs have been used extensively in the treatment of SSc, no therapy to date has been able to reverse or slow the progression of tissue fibrosis or substantially modify the natural progression of the disease. In this Review, we highlight recent studies that shed light on the cellular and molecular mechanisms underlying the fibrotic process in SSc and that identify cellular processes and intra- and extracellular proteins as potential novel targets for therapy in this prototypic multisystemic fibrotic disease.

PMID:
17332883
PMCID:
PMC1804347
DOI:
10.1172/JCI31139
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center